KMID : 1141920210370020120
|
|
Annals of Coloproctology 2021 Volume.37 No. 2 p.120 ~ p.124
|
|
An Unusual Case of Colon Perforation With Multiple Transmural Ulcers After Use of Polmacoxib and Everolimus in a Metastatic Breast Cancer Patient
|
|
Song In-Gyu
Jung Kyung-Uk Kim Hyung-Ook Kim Hung-Dai Chun Ho-Kyung
|
|
Abstract
|
|
|
Everolimus (Afinitor) is an inhibitor of mammalian target of rapamycin. Polmacoxib (Acelex) is a nonsteroidal anti-inflammatory drug that belongs to the cyclooxygenase-2 (COX-2) inhibitor family and is mainly used for treatment of arthritis. Intestinal perforation has not been reported previously as a complication of everolimus, and perforation of the lower intestinal tract caused by a selective COX-2 inhibitor is extremely rare. We present here a case of colon perforation that occurred after use of polmacoxib in a metastatic breast cancer patient who had been treated with everolimus for the preceding six months.
|
|
KEYWORD
|
|
Colon perforation, Everolimus, mTOR inhibitor, Polmacoxib, Nonsteroidal anti-inflammatory agents
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|